Gara Jalqabaatti › Kansaar Onnee Triple-Negative › California › Los Angeles
Qorannoo klinikaalii Kansaar Onnee Triple-Negative Los Angeles, CA keessatti
Qorannoo 27 Kansaar Onnee Triple-Negative f Los Angeles fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UCLA Department of Medicine-Hematology/Oncology, Los Angeles
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- UCLA Jonsson Comprehensive Cancer Center, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- University of California - Los Angeles, Los Angeles
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Namoota walitti qabaa jiraSadarkaa 3
- UCLA Department of Medicine - Hematology & Oncology ( Site 0047), Los Angeles
Intratumoral N17350 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- The Angeles Clinic and Research Institute, Los Angeles
- UCLA - Jonsson Comprehensive Cancer Center, Los Angeles
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Namoota walitti qabaa jiraSadarkaa 2
- Ellison Institute of Technology (EITM), Los Angeles
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Namoota walitti qabaa jiraSadarkaa 3
- Cedars-Sinai Cancer at Beverly Hills, Los Angeles
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- USC/Norris Comprehensive Cancer Center, Los Angeles
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- USC Norris Comprehensive Cancer Center, Los Angeles
SMP-3124LP in Adults With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Cedars Sinai Medical Center, Los Angeles
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Namoota walitti qabaa jiraSadarkaa 2/3
- USC/Norris Comprehensive Cancer Center, Los Angeles
- Valkyrie Clinical Trials, Los Angeles
Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Cedars-Sinai Medical Center, Los Angeles
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- University of California Los Angeles Medical Center, Los Angeles
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Cedars-Sinai Medical Center, Los Angeles
- Cedars-Sinai Medical Center Beverly Hills, Los Angeles
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Namoota walitti qabaa jiraSadarkaa 1
- University of California LA, Los Angeles
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Namoota walitti qabaa jiraSadarkaa 1
- USC Norris Comprehensive Cancer Center /ID# 279603, Los Angeles
Study of XB010 in Subjects With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- UCLA Department of Medicine - Hematology/Oncology, Los Angeles
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Start Lacn, Los Angeles
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1
- USC / Norris Comprehensive Cancer Center, Los Angeles
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- University of Southern California, Los Angeles
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
Namoota walitti qabaa jiraSadarkaa 2
- Cedars-Sinai Medical Center, Los Angeles
Access to Genetic Testing in Underserved Patients With Cancer
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- USC / Norris Comprehensive Cancer Center, Los Angeles
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- Los Angeles Cancer Network (LACN) - Good Sam, Los Angeles
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1/2
- University of Southern California, Los Angeles
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Namoota walitti qabaa jiraSadarkaa 1/2
- UCLA Medical Center, Los Angeles
A Study of NX-1607 in Adults With Advanced Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- University of Southern California, Los Angeles
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Valkyrie Clinical Trials, Los Angeles
Qorannoo Kansaar Onnee Triple-Negative magaalota biroo keessatti
- Houston, TXQorannoo 42
- New York City, NYQorannoo 31
- Nashville, TNQorannoo 28
- Boston, MAQorannoo 26
- San Antonio, TXQorannoo 23
- St. Louis, MOQorannoo 21
- Arlington, VAQorannoo 20
- Atlanta, GAQorannoo 20
- Dallas, TXQorannoo 18
- Chicago, ILQorannoo 16
- Columbus, OHQorannoo 16
- Grand Rapids, MIQorannoo 15
Qorannoo biroo Los Angeles keessatti
- Kansara Qara'a Non-Small CellQorannoo 87
- Saree (Gosoota Hunda)Qorannoo 74
- Saree OljooQorannoo 73
- Kansarii ProstateQorannoo 61
- Kansarii ColorectalQorannoo 59
- Kansara MetastatikiiQorannoo 57
- Kansarii OvariiQorannoo 50
- Dhibee QaraQorannoo 45
- Kansa Selii Skwaamoo Mataa fi MormaQorannoo 42
- Kansarii PancreasQorannoo 35
- Kansa EndometiriyaaliiQorannoo 34
- MelanomaQorannoo 34
Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.